Aerovate Therapeutics (AVTE)
(Delayed Data from NSDQ)
$18.90 USD
+2.56 (15.67%)
Updated Jun 5, 2024 04:00 PM ET
After-Market: $18.97 +0.07 (0.37%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth D Momentum F VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
AVTE 18.90 +2.56(15.67%)
Will AVTE be a Portfolio Killer in June?
Zacks Investment Research is releasing its prediction for AVTE based on the 1-3 month trading system that more than doubles the S&P 500.
Other News for AVTE
Notable Wednesday Option Activity: AVTE, MDGL, BASE
Jefferies Sticks to Its Buy Rating for Aerovate Therapeutics (AVTE)
Analysts Offer Insights on Healthcare Companies: Monte Rosa Therapeutics (GLUE) and Aerovate Therapeutics (AVTE)
Analysts Are Bullish on Top Healthcare Stocks: Ascendis Pharma (ASND), Aerovate Therapeutics (AVTE)
Analysts Are Bullish on Top Healthcare Stocks: Aerovate Therapeutics (AVTE), Exact Sciences (EXAS)